

Receipt



Applicant	Brancato et al.
Serial No.	09/901,320
Filing Date	July 9, 2001
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	118.002US01
Title: USE OF UBIQUINONE Q10 FOR THE LOCAL TREATMENT AND PREVENTION OF POST-SURGICAL OPHTHALMOLOGIC PATHOLOGIES	

TRANSMITTAL
FORM UNDER
37 CFR 1.8
(SMALL ENTITY)

Commissioner for Patents
Washington, DC 20231

Enclosures

The following documents are enclosed:

- A Request for Corrected Filing Receipt (1 pg.)
 A copy of Filing Receipt showing change marked in red (3 pgs.)
 A copy of the Combined Declaration and Power of Attorney with omitted information highlighted.
 An itemized return-receipt postcard.

Please charge any additional fees or credit any overpayments to Deposit Account No. 501373.

Submitted By

Name	Thomas W. Leffert	Reg. No.	40,697	Telephone	(612) 312-2204
Signature				Date	September 10, 2001

Certificate of Mailing

I certify that this correspondence, and the documents identified above, are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on September 10, 2001.

Name	Thomas W. Leffert	Signature	
------	-------------------	-----------	--



Applicant	Brancato et al.
Serial No.	09/901,320
Filing Date	July 9, 2001
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket No.	118.002US01

REQUEST FOR
CORRECTED FILING
RECEIPT

Title: USE OF UBIQUINONE Q10 FOR THE LOCAL TREATMENT AND PREVENTION OF POST-SURGICAL OPHTHALMOLOGIC PATHOLOGIES

Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

Applicant hereby requests correction of the Filing Receipt with respect to the above-identified patent application.

Applicant has claimed benefit under 35 U.S.C. 120/365 to PCT/IT00/00434, filed October 30, 2000, and this information did not appear on the filing receipt. A copy of the Combined Declaration and Power of Attorney, revealing that benefit was claimed and said information highlighted, is enclosed.

A copy of the Filing Receipt showing this change marked in red is also enclosed.

Applicants respectfully requests the above-identified error be corrected and that a corrected Filing Receipt be sent to Applicants' Representative at the below address.

Respectfully submitted,

Date: SEP 20, 01



Thomas W. Leffert
Reg. No. 40,697

Attorneys for Applicant
Fogg Slifer & Polglaze, PA
P.O. Box 581009
Minneapolis, MN 55458-1009
Telephone 612-312-2200
Facsimile 612-312-2250



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/901,320	07/09/2001	1614	697	118.002US01	10	24	2

09/105 10/9/01 and
 priority claim? 11/09/01
 status check 09/09/02

Fogg, Slifer & Polglaze, P.A.
 P.O. Box 581009
 Minneapolis, MN 55458-1009

CONFIRMATION NO. 7767

FILING RECEIPT



OC000000006472962

Date Mailed: 08/27/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rosario Brancato, Firenze, ITALY;
 Sergio Capaccioli, Firenze, ITALY;
 Marco Fabrizio Saettone, Viareggio LU, ITALY;
 Nicola Schiavone, Firenze, ITALY;

Assignment For Published Patent Application

Giuseppe Simonelli;

Domestic Priority data as claimed by applicant

Foreign Applications

ITALY RM99A000719 11/25/1999
 PCT/IT00/00434 10/30/2000

If Required, Foreign Filing License Granted 08/23/2001

Projected Publication Date: 12/06/2001

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title



Use of ubiquinone Q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies

Preliminary Class

514

Data entry by : TRAN, DONG-CHAU

Team : OIPE

Date: 08/27/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231